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Abstract
Background—The prognosis of MBM is variable with prolonged survival in a subset. It is
unclear whether MBMs differ from extracranial metastases (EcM) and primary melanomas (PrM).
Methods—To study the biology of MBM we performed histopathologic analysis of tumor blocks
from patients' craniotomy samples and whole genome expression profiling (WGEP) with
confirmatory immunohistochemistry (IHC).
Results—Mononuclear infiltrate and low intratumoral hemorrhage were associated with
prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor
blocks demonstrated that several immune-related BioCarta gene sets were associated with
prolonged OS. WGEP analysis of MBM in comparison with same-patient EcM and PrM showed
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that MBM and EcM were similar—but both differ significantly from PrM. IHC analysis revealed
that peritumoral CD3+ and CD8+ cells were associated with prolonged OS.
Conclusions—MBMs are more similar to EcM compared to PrM. Immune infiltrate is a
favorable prognostic factor for MBM.
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Introduction
Metastases to the brain are the most frequent intracranial tumors in adults.(1) Melanoma is
the most frequent solid cancer to metastasize to the brain.(2) B-Raf inhibitors and
ipilimumab are active against MBM.(3, 4) Mutations in B-Raf and N-Ras proteins are
associated with higher incidence of MBM.(5) No association between B-RafV600E mutations
in MBM and OS was found.(6) MBM exhibit higher levels of phosphoinositide 3-kinase
pathway activation compared to EcM.(7, 8)
The brain microenvironment differs from that of extracranial sites. It lacks lymphatics and
contains glial cells that may influence tumor growth.(9) Blood vessels in brain tumors differ
from normal brain vessels.(10) Immune cells have also been described in a handful of
metastatic solid tumors to the brain, although their prognostic significance is unknown.(11)
To gain insight into the biology of MBM we performed histopathologic analysis followed by
WGEP and confirmatory IHC and in situ hybridization (ISH) analysis of craniotomy tumor
specimens. Our study proposes new prognostic factors for MBM, and may explain clinical
efficacy of immunotherapies in patients with MBM.
Patients and Methods
Patients and Tumors
Under IRB-approved protocols, de-identified cases from patients who underwent
craniotomy for MBM at the University of Pittsburgh Medical Center (UPMC) were obtained
by performing a CoPATH pathology search followed by retrieval of formalin-fixed paraffin-
embedded (FFPE) tumor blocks from craniotomy, EcM, and PrM specimens.
Histopathologic Assessment of MBMs
Hematoxylin and eosin (H&E)-stained sections were reviewed by a neuropathologist (RH)
who was blinded to patient history. Immune infiltrate, hemorrhage, gliosis, pigmentation,
and necrosis, were semi-quantitatively scored on a 0–3+ scale with 0–1+ being absent/low
and 2–3+ being high. Tumor hemorrhage was defined by the presence of fresh hemorrhage,
hematoidin-laden macrophages, organized blood clot, and ruptured vessels or hemorrhage
adjacent to necrotic areas. Hemorrhage was quantitated as low with 0–2 foci of hematoidin,
fresh blood, or organized clot; high with blood occupying >1/3 of the specimen (Figure 1A).
Immune infiltrate was quantitated by the presence of mononuclear cells around blood
vessels and/or within the tumor parenchyma. Low infiltrate was defined as 0–2 perivascular
infiltrates and high infiltrate was defined as >2 perivascular and/or any infiltrates within the
tumor parenchyma (Figure 1B). Melanin was assessed using a combination of H&E and
Gomori's modified iron stain (Figure 1C). Gliosis was defined as the presence of reactive
astrocytes only near the tumor. Necrosis was estimated as a percentage of necrotic tumor.
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Using a blade under the guidance of H&E-staining of every 10th adjacent 5-micron section,
tissues corresponding to non-necrotic tumor devoid of immune infiltrate, hemorrhage, and
glial cells were microdissected. Deparaffinization of tissue pellets, RNA extraction,
purification, and incubation with the Human Ref8 v3 BeadChips (Illumina Inc., San Diego,
CA) followed by scanning on the Illumina BeadStation GX were performed in the UPCI
Cancer Biomarkers Illumina Platform Facility.(12)
Sources of Antibodies
The following primary antibodies were used: CD3 (DAKO, Carpinteria, CA), CD4 (Vector
Laboratories, Burlingame, CA), CD8 (DAKO), CD14 (Vector), CD19 (Leica Microsystems,
Buffalo Grove, IL), Forkhead box P3 (FoxP3, eBiosciences, San Diego, CA), CD247
(Sigma-Aldrich, St. Louis, MO), transforming growth factor beta (TGFβ, Abcam,
Cambridge, MA), and glial fibrillary acidic protein (GFAP, DAKO). The following
antibodies were generated in Dr. Ferrone's lab: HLA class I (HC-10/HC-A2 clones), HLA
class II (LGII-612.14), and tapasin (TO-3).
IHC, ISH and Scoring Definitions
For IHC, FFPE tumor sections were probed with antibodies and stained with Vulcan Fast
Red (Biocare Medical, Concord, CA). CD3, CD4, CD8, CD14, CD19, and CD247-positive
mononuclear cells were scored separately (RH and SM) for peritumoral and intratumoral
compartments, as previously described (Figure 2).(13) Expression of TGFβ, HLA class I/II,
and tapasin by melanoma cells were assessed using the H-score whose median was used as
the cutoff value between high versus low expression. ISHs were performed (BFJ and TAR)
using human-specific sequences for detection of chemokine (CXCL13, CCL19, CCL21)
mRNAs. Autoradiographic exposure times of 35S-labeled riboprobes were 7–10 days.(14)
Statistical Analysis
Cox proportional-hazards modeling was used to identify clinicopathologic variables
associated with OS defined as time-to-death (TTD) from first craniotomy, by fitting a
univariate regression model for each variable. Kaplan–Meier (KM) survival analysis using
the log-rank significance test was also performed for dichotomous variables. Patients who
were still alive between the first craniotomy and March 12, 2012 were censored at the date
of last follow-up. Curves were constructed using IBM SPSS Statistics release 19.0.0
software (IBM Company, Armonk, NY). Variables that were significantly associated with
OS in univariate analysis were subjected to multivariate Cox regression analysis.
Bioinformatics Analysis
Bioinformatics analysis of WGEP data was performed using the Biometric Research
Branch-Array (BRB) Tools software (http://linus.nci.nih.gov/BRB-ArrayTools.html). Data
were quantile-normalized using the lumi R package. Probe sets were excluded from further
analysis if <20% of gene expression data values had ≥1·5-fold change in either direction of
probe set's median value and the percentage of data missing exceeded 50%. To assess
whether specific cellular pathways were associated with OS, we performed survival pathway
analysis on the MBM dataset using the Survival Gene Set analysis (GSA) tool. The Efron-
Tibshirani maxmean test was applied to identify gene sets at a p=0·05 significance level.
Hierarchical clustering analysis was used to assess the degree of association between PrM,
EcM, and MBM using either all genes that passed the filtering criteria or highly discriminant
genes. Highly discriminating genes were selected as differentially expressed between two
same-patient different sites (MBM-EcM, MBM-PrM, and EcM-PrM) using paired t-test.
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Analysis of variance (ANOVA) using all genes that passed the filtering criteria was used to
assess whether MBM are significantly different from EcM and/or PrM. Enrichment analysis
of differentially expressed probe sets to determine their biological annotation to specific
cellular pathways was performed for the same patient EcM-MBM tumor samples using
DAVID database (http://david/abcc.ncifcrf.gov). Enrichment p-value was set to 0.05 after
Benjamini-Hochberg multiple comparison correction testing.
Results
Clinical Characteristics of Patients with MBM
115 patients underwent craniotomy at UPMC between November 1995 and July 2011
(Table 1). 27% and 30% of patients originally presented either with unknown primary(15) or
thin (AJCC stage I) melanoma, respectively. No patients had received vemurafenib or
radiation therapy prior to craniotomy and only 2 out of 9 patients with B-RafV600 mutation
received vemurafenib following craniotomy.
High Immune Infiltrate and Low Hemorrhage in MBM are Associated with Prolonged OS
Due to tumor block availability (n=106), absence of viable tumor cells (n=3), or cytology
specimens (n=2) our final analysis was based on 101 of cases. As shown in Table 2 immune
infiltrate (p=0.006), hemorrhage (p=0.04), recursive partitioning analysis (RPA) class
(p<0.0001), ECOG performance status (p=0.024), and local therapy after craniotomy
(p=0.019) were significantly associated with OS. No significant correlation between B-Raf
mutation status and immune infiltrate or hemorrhage was noted (Pearson's chi-square test
p=0.57 and p=0.49, respectively). Figure 3 shows the Kaplan-Meier OS curves partitioned
by immune infiltrate and hemorrhage. A significant interaction between the `immune
infiltrate' and `hemorrhage' variables was noted (Cox regression test, p=0.0031). In
particular, patients with high immune infiltrate and low/absent hemorrhage had prolonged
OS compared to all remaining patients (543 vs. 164 days, log-rank p<0.001). Cox multiple
regression analysis showed that immune infiltrate (p=0.008), ECOG performance status
(p=0.043), RPA (p<0.0001), and local therapy (p=0.0005) remained significant predictors of
OS.
WGEP of MBM Identifies Pathways Associated with Outcome
To gain insight regarding cellular processes associated with survival in MBM, we performed
WGEP of RNA obtained from FFPE brain sections. Only 29 patients' tumor blocks were
suitable for microdissection. Survival analysis using the log-rank test of the entire 101-
patient cohort compared with the 29-patient subset revealed no significant difference in time
to death from craniotomy [p=0.17, median survival is 177 versus 246 days, hazard ratio
(HR) 0.72, 95% confidence intervals (95% CI) 0.49–1.13]. 15,067 probe sets (out of a total
of 24,526) that passed the filtering criteria were used to perform Cox proportional hazards
model to identify gene sets associated with survival. Table 3 shows 49 (out of a total of 284)
prognostic BioCarta pathways. The leading gene sets that were associated with prolonged
OS are immune-related, with the T-cell receptor (TCR) function pathway being the most
significant category. In contrast, pathways associated with shortened OS involved genes
associated with hypoxia, the lissencephaly gene (LIS1) in neuronal migration and
development, and oxidative stress, among others.
Validation of WGEP and Histopathologic Data
Since one of the gene set categories associated with prolonged OS was the TCR pathway,
we performed IHC analysis of MBM for immune cell subsets. High peritumoral CD3+ and
CD8+ mononuclear cells were significantly associated with prolonged OS (Table 4). To
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assess whether melanoma-infiltrating immune cells were functional within MBMs, we
stained sections with CD247, the ζ chain of the TCR that is essential for amplification of
TCR signaling and frequently lost in cancer.(16) Although CD247+ mononuclear cells were
detectable, high numbers of CD247+ cells were infrequently observed. In addition, neither
peritumoral CD4+ and CD14+ mononuclear cells nor the presence of any intratumoral
mononuclear cell population tested were associated with prolonged OS (Table 4).
We then asked whether the higher immune cell infiltrate is secondary to either higher
expression of molecules involved in antigen presentation machinery by melanoma cells (e.g.
HLA class I, class II, tapasin) or to lower expression of the immunosuppressive cytokine
TGFβ by melanoma cells or to the expression of the chemokines CCL19, CCL21, and
CXCL13 by mononuclear cells (17) or to lower abundance of naturally-occurring T
regulatory cells (e.g. FoxP3+). The expression-abundance of none of these molecules-
immune cell subsets was associated with prolonged OS (Table 4).
MBM are Biologically Closer to EcM than PrM
To assess whether MBM differ from other EcM or PrM in their WGEP, we performed
WGEP of 72 samples. Same-patient MBM-EcM, MBM-PrM, and EcM-PrM pairs were
available from 26, 12, and 12 patients, respectively. ANOVA using all probe sets showed
that MBM and EcM cluster significantly differently from PrM (p<0.0001). Shown in Figure
4 is a dendrogram of the 72 samples that was constructed using all 15,067 probe sets. To
measure the degree of similarity between MBM, EcM, PrM we used the Euclidean distance
metric and average linkage and calculated the distances between same-patient MBM-EcM,
MBM-PrM, and EcM-PrM. The distance between MBM-EcM was significantly smaller,
compared to distances calculated between the other two groups (MBM-PrM and EcM-PrM)
when clustering was performed on all 72 samples using all 15,067 probe sets (mean: 124
versus 169 and 162, respectively; ANOVA p=0.09, t-test to compare the distance between
MBM-EcM and MBM-PrM as well as between MBM-EcM and EcM-PrM have a p-value of
0.04 for both).
One of the probe sets that was significantly upregulated in MBM, as opposed to EcM and
PrM, was GFAP, a protein expressed by reactive astrocytes. IHC analysis confirmed that
GFAP was detectable only in astrocytes of 21 MBM and absent in all six stained EcM.
GFAP+ cells were not only surrounding melanoma cells, but were also detectable in clusters
or islands within the tumor (Figure 2B). DAVID analysis of the differentially expressed
genes between same-patient EcM-MBM tumor samples failed to reveal cellular processes
that were significantly different between EcM and MBM.
Discussion
Patients with metastatic melanoma live longer, in the current era of effective new therapies.
(18, 19) Clinical trials using these agents in patients with MBM have shown efficacy(3, 4)
although the mechanism for their effects in MBM is unclear. Our immunohistochemical and
GSA of MBM show that high degree of immune infiltrate and low intratumoral hemorrhage
in MBM tumor tissues are favorable prognostic factors for patients who undergo craniotomy
for MBM. Equally important, WGEP of MBM demonstrates similarity to EcM and both
expression profiles differ from PrM. The role of stromal components, such as the immune
infiltrate or reactive glial (GFAP+) cells interdigitating with melanoma, along with the
similarity between EcM and MBM in gene expression suggests that signals from the stroma,
and to a lesser extent the biology of melanoma cells, play an important role in determining
prognosis. The clinical-prognostic significance of the tumor microenvironment mediating
cross-talk with cancer cells has been shown in several other solid tumors.(13)
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The prognostic significance of the high CD3+/CD8+ immune infiltrate in MBM is supported
by histopathologic, IHC/ISH, and WGEP analyses. A previous study in patients with
glioblastoma multiforme showed that glia-associated CD8+ infiltrates correlate with long-
term survival.(20) However, peritumoral, but not intratumoral, T-cells were associated with
prolonged OS, as previously described.(21) The lack of high numbers of intratumoral
infiltrates as well as active (e.g. CD247+) mononuclear cells may account for the short OS
seen in patients with MBM. However, the presence of immune cells provides an opportunity
for immunotherapeutic approaches. The lack of association between other mononuclear
populations, or expression of various components of the antigen expression machinery,
immunosuppressive cytokines (e.g. TGFβ), and chemokines by melanoma cells with OS
suggests that other factors may be involved.
This study provides new insights regarding the biology of MBM in relation to EcM and
PrM. Although several genes overexpressed in PrM include among others, keratins, which
may imply contamination, several keratins are indeed expressed by melanoma cells.(22) In
addition, a significant number of genes that were previously found differentially expressed
between PrM and/or human epidermal melanocytes versus metastatic melanomas were also
found in our 514 gene list (e.g. KRT6B/14/16/17, LOR, KLK7, GJB6, PITX1, CST, DSC).
(23) In contrast, we were surprised to find that only 23 out of the 514-gene list were
differentially expressed between EcM and MBM. The gene expression similarity between
MBM and EcM, which remained significant using all 15,067 probe sets for the clustering
analysis, is in line with a recent study regarding the concordance of B-Raf and N-Ras
mutations in melanoma metastases(24, 25) as well as the concordance of gene copy number
variations between same-patient EcM and MBM.(25) This similarity is clinically relevant,
because it explains results from ongoing clinical trials using B-Raf inhibitors in patients with
MBM, which show that the response rate of MBMs is not significantly different from that of
EcM.(3) The biological similarity and interconnectivity between EcM and MBM may
explain the fact that the outcome of patients with MBM is not solely dependent on the
effective control of MBM, but also relates to control of EcM since only 50% of patients with
MBM die from events directly associated with MBM.
Our study was unable to investigate whether melanoma cells within the brain acquire
neuronal cell characteristics, as was previously described.(26) However proteins, such as the
LIS1, which is associated with neuronal migration and its corresponding BioCarta pathway
was associated with shortened OS in patients with MBM in our study (Table 3) was
expressed by melanoma cells in MBMs as well as melanoma cell lines (data not shown).
Despite the similarities between EcM and MBM, our WGEP analysis identified a number of
genes that were differentially expressed between MBM and EcM, such as GFAP (Figure
4A). Since GFAP is solely expressed by glial cells, our frequent observation of glial cells
interspersed within, but not solely surrounding melanoma lesions, should imply an intimate
relation with melanoma cells that may have clinical implications, such as, for example, the
glial-mediated protection of melanoma cells from chemotherapies(27) or the glial-mediated
upregulation of the PI3K pathway in neighboring melanoma cells that have metastasized to
the brain.(7, 8) This latter finding may imply that targeted therapies against the PI3K
pathway may be relevant in patients with MBM, especially those who escape B-Raf
inhibition.(8) Therefore, the role of the glial microenvironment needs to be further
characterized as it may provide clues regarding inferior responses of traditional cytotoxics or
failures to the brain from treatment with B-Raf inhibitors.(8)
In summary, we present a translational analysis of a patient cohort with MBM, EcM, and
PrM tumor biopsies that illuminates the biological factors that are important in established
MBM. Although the tumor tissues that were selected and analyzed for histopathology,
immunohistochemistry and WGEP were derived from patients who underwent craniotomy
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within a single large institution, the findings and conclusions have important clinical
implications. First, patients with MBM have variable prognosis and high levels of immune
infiltrate and low levels of hemorrhage identify a patient subgroup with improved prognosis.
Second, the pursuit of the expanding number of systemic immunotherapies in MBM may be
indirectly supported by these findings.
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Figure 1. Tumor sections of MBMs
A. H&E-stained sections that were scored high and low hemorrhage (black open arrows). B.
H&E-stained sections that show high and low immune infiltrate (yellow open arrows). C.
Sections were stained with potassium ferrocyanide and counterstained with nuclear fast red
(Kernechtrot), if adjacent H&E-stained sections showed pigmentation. Hemosiderin is
stained blue (red open arrows) and melanin remains brown (yellow arrows).
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Figure 2. IHC staining of brain tumor sections
Tumor sections were stained with Vulcan Fast Red and counterstained with hematoxylin. A.
CD3 stain. Representative pictures (20× magnification) show low and high degrees of
intratumoral (upper row) or peritumoral-perivascular infiltrate (lower row). B. GFAP stain.
GFAP+ cells (blue arrows) are not only present in tumor periphery (left image) but also
within the tumor (middle and right image).
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Figure 3. Kaplan-Meier curves of prognostic histopathologic factors in MBM
A. Immune infiltrate. B. Intratumoral hemorrhage. C. Immune infiltrate and intratumoral
hemorrhage.
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Figure 4. Assessment of the degree of similarity between MBM, EcM, and PrM
Dendrogram plot shows the gene expression relatedness of the 72 samples based on the
15,067 probe sets that passed the filtering criteria. Each sample is labeled by its site (B,
brain, red; E, extracranial, blue; P, primary, black) and patient number. Brackets below
patient samples link same-patient MBM and EcM (black closely related; grey distantly
related; red, closely related distant metastases, EcM or MBM, with PrM). Numbers shown
above nodes (red dots) are Euclidean distances calculated between two samples (e.g. B1-E1,
B15-E15, B31-E31, E9-P9) based on the Euclidean distance scale shown to the left.
Euclidean distance is one of the metrics used to quantify the difference between two points
in space, which in our study are each individual tumor tissue samples. The difference
between each tumor tissue samples is based on expression data from gene that are common
to the sites. The larger the Euclidean distance, the larger the separation between tumor pairs.
Hamilton et al. Page 12

























Hamilton et al. Page 13
Table 1
Clinicopathologic characteristics of patients who underwent craniotomy.







 Unknown primary (All Criteria) 22




  B-RafV600E 6
  B-RafV600K 3








Patients were considered to have `partial' criteria for unknown primary(15) if they had no knowledge of excision of a pigmented lesion.
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Table 2
Clinicopathologic factors in relation to OS in patients with MBMs.
Variable No of Pts Median Survival (days) Log-Rank P KM Estimator HR (95% CI)
Age at Craniotomy
 <65 80 189 0.33 1.30 (0.75–2.15)
 >65 21 137
Sex
 Male 63 154 0.10 1.44 (0.94–2.26)
 Female 38 228
ECOG Performance Status
 0 12 481
 1 61 191 0.024 1.71 (1.05–2.70)
 2 24 142
 3 4 8
Extracranial Disease
 Absent 48 143 0.36 0.82 (0.54–1.26)
 Present 51 191
 Unknown 2 143
RPA
 1 26 475
 >1 74 151 <0.0001 3.4 (1.97–6.23)
Systemic Therapy Prior to Craniotomy
 Immunotherapy 31 244 0.81 (0.50–1.29)
 Chemotherapy 8 185 0.66 1.26 (0.55–2.52)
 Sequential or Combination Therapy 4 335 0.78 (0.23–1.90)
 No systemic therapy 58 154
Number of brain lesions
 1 49 181 0.61 0.88 (0.52–1.44)
 >1 29 212
Systemic Therapy After Craniotomy
 Immunotherapy 7 212 0.43 (0.13–1.06)
 Chemotherapy 33 222 0.13 0.95 (0.60–1.48)
 Sequential or Combination Therapy 4 1011 0.35 (0.09–0.98)
 No systemic therapy 57 133
Local Therapy After Craniotomy
0.019
 Stereotactic radiosurgery only 50 248 0.34 (0.20–0.58)
 Whole brain irradiation only 7 253 0.37 (0.14–0.88)
 Repeat Craniotomy 4 170 0.76 (0.22–2.00)
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Variable No of Pts Median Survival (days) Log-Rank P KM Estimator HR (95% CI)
 Combination local therapy 17 232 0.41 (0.21–0.78)
 No local therapy 23 57
Immune Infiltrate
 Low 56 160
 High 44 259 0.006 0.54 (0.35–0.84)
 Non assessable 1
Hemorrhage
 Low 42 234
 High 58 160 0.04 1.58 (1.02–2.48)
 Non assessable 1
Necrosis
 Low 56 156 0.56 0.88 (0.57–1.34)
 High 44 202
 Non assessable 1
Melanin
 Low 73 181
 High 23 191 0.28 0.75 (0.44–1.24)
 Non assessable 5
Gliosis
 Low 9 120 0.25 0.64 (0.32–1.48)
 High 45 164
 Non assessable 47
Presented p-values are from univariate analysis.
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Table 3
Biocarta pathways that were differentially expressed in MBMs.
Pathways Associated with Good Prognosis GSA test p-value
1 CD3 Complex < 0.005
2 T helper (Th) Surface Molecules < 0.005
3 HIV-Induced T-Cell Apoptosis < 0.005
4 B-Cell Surface Molecules < 0.005
5 Th1/Th2 Differentiation < 0.005
6 Role of Tob in T-Cell Activation < 0.005
7 Activation of Csk Inhibits Signaling through the TCR 0.005
8 Lck and Fyn Kinases Initiate TCR Activation 0.005
9 Cells/Molecules Involved in Local Acute Inflammatory Response 0.005
10 Dendritic Cells Regulate Th1/Th2 Development 0.005
Pathways Associated with Adverse Prognosis
1 West Nile Virus < 0.005
2 Y Branching of Actin Filaments 0.005
3 Hypoxia-Inducible Factor 0.005
4 Regulation of ck1/cdk5 by type 1 Glutamate Receptors 0.005
5 fMLP-Induced Chemokine Expression in HMC-1 cells 0.005
6 Free Radical-Induced Apoptosis 0.01
7 Repression of Pain Sensation by DREAM 0.015
8 Transcription Regulation by Methyltransferase of CARM1 0.015
9 Cadmium Induces DNA Synthesis and Proliferation in Macrophages 0.02
10 Lissencephaly Gene in Neuronal Migration and Development 0.025
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